|
|
|
- The INFINITI™ Factor II assay is available as an in-vitro diagnostic assay, (IVD).
- The INFINITI System Assay for Factor II is indicated for use as an aid to diagnosis in the evaluation of patients with suspected thrombophilia.
- The INFINITI System Assay for Factor II is used to determine genetic variants in Factor II (Prothrombin).
- The INFINITI System Assay for Factor II utilizes the Factor II Intellipac™, Factor II Amp Mix and Factor II BioFlimChip™ Microarray.
- The INFINITI Factor II assay is automated by the INFINITI Analyzer.
|
|
 |
|
|
Determination of genetic variant for Factor II |
|
|
Rapid turnaround time enhances workflow efficiency |
|
|
|
Replicate determinations on a single BioFilmChip Microarray ensures quality results |
|
Factor II (Prothrombin) G20210A |
0.2 - 2.0 ml of peripheral whole blood in EDTA (purple-top) tube
50 ng DNA / reaction
|
|
|
|
Product No. |
Product Name |
Description |
Pack Size |
|
01 102
01 202
01 302
|
INFINITI Factor II BioFilmChip
INFINITI Factor II Intellipac
INFINITI Factor II Amp Mix |
12 BioFilmChips/magazine
24 tests/Intellipac
250 ul/vial |
4 magazines/pack
2 Intellipac/pack
4 vials/pack |
|
Please contact AutoGenomics to obtain product information.
- The Factor II (Prothrombin) variant gene is the second most common genetic defect for inherited thrombosis.
- The increased risk of venous thrombosis in patients who are heterozygous for the prothrombin (G20210A) gene
polymorphism is 3-fold.1
- Homozygotes for this polymorphism have been described but are very uncommon.1
- Patients with a previous, or current, thrombotic event that have the prothrombin (G20210A) gene polymorphism are
potentially at increased risk for recurrence.1
- Patients with the prothrombin (G20210A) mutation are at increased risk of thrombosis when exposed to other risk factors
such as:
- (1) smoking
- (2) pregnancy
- (3) Obesity
- (4) Oral Contraceptives
- (5) Immobility1
- "The risk of thrombosis is substantially increased for patients with multiple genetic risk factors (i.e., the "double hithypothesis") including the prothrombin (G20210A) gene mutation, Factor V Leiden Leiden mutation, hyperhomocysteinemia, methylenetetrahydrofolate reductase (MTHFR) thermolabile polymorphism, protein C deficiency, protein S deficiency, and antiphospholipid antibody syndrome(s)."1
- Definition and confirmation of the prothrombin (G20210A) gene polymorphism is necessary for genetic counseling of
patients for themselves and family members.1
References
1. http://pathology.mc.duke.edu/coag/PTGlflyer2.html |
Factor II
